|
Steelman, Linda S; Navolanic, Patrick; Chappell, William H et al. (2011) Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle 10:3003-15
|
|
Sokolosky, Melissa L; Stadelman, Kristin M; Chappell, William H et al. (2011) Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget 2:538-50
|
|
Taylor, Jackson R; Lehmann, Brian D; Chappell, William H et al. (2011) Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget 2:610-26
|
|
McCubrey, James A; Abrams, Stephen L; Stadelman, Kristin et al. (2010) Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Adv Enzyme Regul 50:285-307
|
|
Abrams, Stephen L; Steelman, Linda S; Shelton, John G et al. (2010) Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle 9:1839-46
|
|
Steelman, Linda S; Abrams, Stephen L; Shelton, John G et al. (2010) Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle 9:1629-38
|
|
Abrams, Stephen L; Steelman, Linda S; Shelton, John G et al. (2010) The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9:1781-91
|
|
Martelli, Alberto M; Evangelisti, Camilla; Chiarini, Francesca et al. (2010) The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 1:89-103
|
|
Misaghian, N; Ligresti, G; Steelman, L S et al. (2009) Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia 23:25-42
|
|
Chiarini, Francesca; Fala, Federica; Tazzari, Pier Luigi et al. (2009) Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 69:3520-8
|
Showing the most recent 10 out of 72 publications
